Clinical validation of the tempus xT next-generation targeted oncology sequencing assay.
next-generation sequencing assay validation
tumor profiling
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
22 Mar 2019
22 Mar 2019
Historique:
received:
03
08
2018
accepted:
03
02
2019
entrez:
2
5
2019
pubmed:
2
5
2019
medline:
2
5
2019
Statut:
epublish
Résumé
We developed and clinically validated a hybrid capture next generation sequencing assay to detect somatic alterations and microsatellite instability in solid tumors and hematologic malignancies. This targeted oncology assay utilizes tumor-normal matched samples for highly accurate somatic alteration calling and whole transcriptome RNA sequencing for unbiased identification of gene fusion events. The assay was validated with a combination of clinical specimens and cell lines, and recorded a sensitivity of 99.1% for single nucleotide variants, 98.1% for indels, 99.9% for gene rearrangements, 98.4% for copy number variations, and 99.9% for microsatellite instability detection. This assay presents a wide array of data for clinical management and clinical trial enrollment while conserving limited tissue.
Identifiants
pubmed: 31040929
doi: 10.18632/oncotarget.26797
pii: 26797
pmc: PMC6481324
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2384-2396Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST All authors have a financial relationship as employees of Tempus Labs, Inc.
Références
Biostatistics. 2004 Oct;5(4):557-72
pubmed: 15475419
Genome Res. 2005 Sep;15(9):1284-91
pubmed: 16109971
Genome Res. 2007 Nov;17(11):1665-74
pubmed: 17921354
Nat Methods. 2009 Jan;6(1):99-103
pubmed: 19043412
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
BMC Bioinformatics. 2013;14 Suppl 11:S1
pubmed: 24564169
Mol Oncol. 2014 Jul;8(5):859-73
pubmed: 24768039
Bioinformatics. 2014 Sep 1;30(17):2503-5
pubmed: 24812344
Genome Biol. 2014 Jun 26;15(6):R84
pubmed: 24970577
Bioinformatics. 2014 Dec 1;30(23):3310-6
pubmed: 25143287
Arch Pathol Lab Med. 2015 May;139(5):642-9
pubmed: 25927147
JAMA Oncol. 2015 Apr;1(1):40-9
pubmed: 26182302
Nat Methods. 2015 Oct;12(10):966-8
pubmed: 26258291
J Clin Oncol. 2015 Nov 10;33(32):3817-25
pubmed: 26304871
Cancer Res. 2016 Jul 1;76(13):3690-701
pubmed: 27197177
JAMA Oncol. 2016 Nov 1;2(11):1452-1459
pubmed: 27273579
Oncologist. 2016 Nov;21(11):1315-1325
pubmed: 27566247
Genome Med. 2016 Nov 4;8(1):117
pubmed: 27814769
Genet Med. 2017 Feb;19(2):249-255
pubmed: 27854360
N Engl J Med. 2016 Dec 8;375(23):2255-2262
pubmed: 27959684
Am J Clin Dermatol. 2017 Feb;18(1):1-15
pubmed: 27988837
J Mol Diagn. 2017 Jan;19(1):4-23
pubmed: 27993330
Oncology (Williston Park). 2017 Mar 15;31(3):158, 168
pubmed: 28299751
Curr Probl Cancer. 2017 May - Jun;41(3):182-193
pubmed: 28372823
Oncotarget. 2017 Jun 13;8(24):39254-39267
pubmed: 28424409
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Eur J Cancer. 2017 Sep;82:128-136
pubmed: 28666240
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
Virchows Arch. 2018 Jan;472(1):125-133
pubmed: 29143108
Eur J Endocrinol. 2018 Feb;178(2):173-180
pubmed: 29187509
Medicine (Baltimore). 2017 Dec;96(48):e8931
pubmed: 29310385
Nat Biotechnol. 2018 Jan 10;36(1):46-60
pubmed: 29319699
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Cell. 2018 Apr 5;173(2):321-337.e10
pubmed: 29625050
Oncotarget. 2018 May 25;9(40):25826-25832
pubmed: 29899824